Curcumin as a therapeutic agent in liver cancer: a systematic review of preclinical models and mechanisms
Abstract Background Curcumin, a bioactive compound derived from Curcuma longa, has gained attention for its potential therapeutic effects in liver cancer. We reviewed current literature to evaluate the efficacy of curcumin in liver cancer models, such as anti-proliferative, pro-apoptotic, anti-infla...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40001-025-02922-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849333138160877568 |
|---|---|
| author | Ke Ma Ye Shen Jiahui Hu JueBao Li Xingru Zhang |
| author_facet | Ke Ma Ye Shen Jiahui Hu JueBao Li Xingru Zhang |
| author_sort | Ke Ma |
| collection | DOAJ |
| description | Abstract Background Curcumin, a bioactive compound derived from Curcuma longa, has gained attention for its potential therapeutic effects in liver cancer. We reviewed current literature to evaluate the efficacy of curcumin in liver cancer models, such as anti-proliferative, pro-apoptotic, anti-inflammatory, or anti-metastatic roles. This systematic review focused on experimental methods, dosages, and underlying mechanisms. Methods A comprehensive literature search was conducted across PubMed, Web of Science, Embase, and Google Scholar until December 2024. Inclusion criteria were studies using in vivo or in vitro models to assess curcumin's effects on liver cancer, with comparisons to control groups. A total of 26 studies (8 in vivo, 14 in vitro, 4 combined) were included. Data on curcumin administration methods, dosages, and outcomes were extracted. Study quality was assessed using a six-item scale. Descriptive statistics were used for data analysis with SPSS (Version 22.0). Results From the initial 1048 studies retrieved, 27 met the inclusion criteria. In vivo studies were conducted on various animals strains (C3H/HeN mice, Wistar rats, B6C3F1 mice, BALB/c nude mice and C57BL/6 mice). Curcumin was administered via oral (8 studies), intraperitoneal (2 studies), intragastric (1 study) and intravenous (1 study) routes, with 8 studies incorporating a dose gradient. The majority of studies used chemically-induced models, including N-diethylnitrosamine (DEN) and nitrosodiethylamine (NDEA) models, as well as subcutaneous injections of liver cancer cell lines (HepG2, Bel7402). The included studies employed various techniques, including Western blotting, RT-PCR, flow cytometry, and migration assays. Curcumin significantly induced apoptosis in liver cancer cells, with 14 studies reporting dose-dependent increases in apoptosis markers such as caspase-3 and Bax expression. Anti-inflammatory effects were evident in 5 studies, with curcumin inhibiting NF-κB activation, a key pathway in liver cancer progression. Additionally, antioxidant and anti-angiogenic properties were observed, as curcumin reduced lipid peroxidation and decreased VEGF expression. Two studies highlighted curcumin’s potential in suppressing metastasis, with dose-dependent inhibition of liver cancer cell migration and invasion. The quality of included studies varied, with 21 out of 27 studies employing random allocation and 8 using blinded outcome assessments. Conclusions Curcumin demonstrates promising anti-cancer effects, including apoptosis induction, inflammation modulation, and metastasis inhibition. However, variability in study designs and lack of clinical trials necessitate standardized protocols and further clinical investigations to confirm its therapeutic potential in liver cancer treatment. |
| format | Article |
| id | doaj-art-c551bdc225064bd8979897ecb404786c |
| institution | Kabale University |
| issn | 2047-783X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | European Journal of Medical Research |
| spelling | doaj-art-c551bdc225064bd8979897ecb404786c2025-08-20T03:45:57ZengBMCEuropean Journal of Medical Research2047-783X2025-07-0130111610.1186/s40001-025-02922-8Curcumin as a therapeutic agent in liver cancer: a systematic review of preclinical models and mechanismsKe Ma0Ye Shen1Jiahui Hu2JueBao Li3Xingru Zhang4Center for Rehabilitation Medicine, Rehabilitation & Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Rehabilitation Medicine, Rehabilitation & Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Rehabilitation Medicine, Rehabilitation & Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Rehabilitation Medicine, Rehabilitation & Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Rehabilitation Medicine, Rehabilitation & Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeAbstract Background Curcumin, a bioactive compound derived from Curcuma longa, has gained attention for its potential therapeutic effects in liver cancer. We reviewed current literature to evaluate the efficacy of curcumin in liver cancer models, such as anti-proliferative, pro-apoptotic, anti-inflammatory, or anti-metastatic roles. This systematic review focused on experimental methods, dosages, and underlying mechanisms. Methods A comprehensive literature search was conducted across PubMed, Web of Science, Embase, and Google Scholar until December 2024. Inclusion criteria were studies using in vivo or in vitro models to assess curcumin's effects on liver cancer, with comparisons to control groups. A total of 26 studies (8 in vivo, 14 in vitro, 4 combined) were included. Data on curcumin administration methods, dosages, and outcomes were extracted. Study quality was assessed using a six-item scale. Descriptive statistics were used for data analysis with SPSS (Version 22.0). Results From the initial 1048 studies retrieved, 27 met the inclusion criteria. In vivo studies were conducted on various animals strains (C3H/HeN mice, Wistar rats, B6C3F1 mice, BALB/c nude mice and C57BL/6 mice). Curcumin was administered via oral (8 studies), intraperitoneal (2 studies), intragastric (1 study) and intravenous (1 study) routes, with 8 studies incorporating a dose gradient. The majority of studies used chemically-induced models, including N-diethylnitrosamine (DEN) and nitrosodiethylamine (NDEA) models, as well as subcutaneous injections of liver cancer cell lines (HepG2, Bel7402). The included studies employed various techniques, including Western blotting, RT-PCR, flow cytometry, and migration assays. Curcumin significantly induced apoptosis in liver cancer cells, with 14 studies reporting dose-dependent increases in apoptosis markers such as caspase-3 and Bax expression. Anti-inflammatory effects were evident in 5 studies, with curcumin inhibiting NF-κB activation, a key pathway in liver cancer progression. Additionally, antioxidant and anti-angiogenic properties were observed, as curcumin reduced lipid peroxidation and decreased VEGF expression. Two studies highlighted curcumin’s potential in suppressing metastasis, with dose-dependent inhibition of liver cancer cell migration and invasion. The quality of included studies varied, with 21 out of 27 studies employing random allocation and 8 using blinded outcome assessments. Conclusions Curcumin demonstrates promising anti-cancer effects, including apoptosis induction, inflammation modulation, and metastasis inhibition. However, variability in study designs and lack of clinical trials necessitate standardized protocols and further clinical investigations to confirm its therapeutic potential in liver cancer treatment.https://doi.org/10.1186/s40001-025-02922-8CurcuminLiver cancerPreclinical studiesIn vivo and in vitro modelsSystematic review |
| spellingShingle | Ke Ma Ye Shen Jiahui Hu JueBao Li Xingru Zhang Curcumin as a therapeutic agent in liver cancer: a systematic review of preclinical models and mechanisms European Journal of Medical Research Curcumin Liver cancer Preclinical studies In vivo and in vitro models Systematic review |
| title | Curcumin as a therapeutic agent in liver cancer: a systematic review of preclinical models and mechanisms |
| title_full | Curcumin as a therapeutic agent in liver cancer: a systematic review of preclinical models and mechanisms |
| title_fullStr | Curcumin as a therapeutic agent in liver cancer: a systematic review of preclinical models and mechanisms |
| title_full_unstemmed | Curcumin as a therapeutic agent in liver cancer: a systematic review of preclinical models and mechanisms |
| title_short | Curcumin as a therapeutic agent in liver cancer: a systematic review of preclinical models and mechanisms |
| title_sort | curcumin as a therapeutic agent in liver cancer a systematic review of preclinical models and mechanisms |
| topic | Curcumin Liver cancer Preclinical studies In vivo and in vitro models Systematic review |
| url | https://doi.org/10.1186/s40001-025-02922-8 |
| work_keys_str_mv | AT kema curcuminasatherapeuticagentinlivercancerasystematicreviewofpreclinicalmodelsandmechanisms AT yeshen curcuminasatherapeuticagentinlivercancerasystematicreviewofpreclinicalmodelsandmechanisms AT jiahuihu curcuminasatherapeuticagentinlivercancerasystematicreviewofpreclinicalmodelsandmechanisms AT juebaoli curcuminasatherapeuticagentinlivercancerasystematicreviewofpreclinicalmodelsandmechanisms AT xingruzhang curcuminasatherapeuticagentinlivercancerasystematicreviewofpreclinicalmodelsandmechanisms |